1. Academic Validation
  2. Tumor Mechanobiology-Inspired Nanomechanics: Piezo1 Mediated Tumor-Associated Macrophages Reprogramming and Exosome-Driven Immune Amplification

Tumor Mechanobiology-Inspired Nanomechanics: Piezo1 Mediated Tumor-Associated Macrophages Reprogramming and Exosome-Driven Immune Amplification

  • ACS Nano. 2025 Dec 16;19(49):41746-41764. doi: 10.1021/acsnano.5c14785.
Zichen Yang 1 Rongjie Li 1 Lulu An 1 Xiaoyou Zhang 1 Jianwei Cheng 2 Yanni Cai 1 Yang Li 3 Haiqing Dong 3 Yongyong Li 2 Yan Li 1
Affiliations

Affiliations

  • 1 Shanghai Skin Disease Hospital, Department of Pharmacy, School of Medicine, Tongji University, Shanghai 200092, China.
  • 2 Shanghai Skin Disease Hospital, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200092, China.
  • 3 Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration, Ministry of Education, Tongji Hospital, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200092, China.
Abstract

Mechanosensitive signaling pathways in immune cells drive exhaustion and ultimately facilitate tumor immune escape. In situ mechanical modulation strategies, leveraging the tumor's mechanical features, may provide a distinctive perspective for immunotherapy. We repurpose conventional silica nanocarriers from mere "drug delivery vehicles" into "Piezo1 mechanotransduction modulators" by precisely tuning their mechanical properties to directly intervene in tumor-associated macrophages (TAMs) mechanosignaling. Our study revealed that Piezo1 acts as a mechano-immunological switch in tumors: its downregulation in large tumors promotes M2-like TAMs polarization, whereas its upregulation in small tumors drives M1-mediated antitumor immunity. This directly couples mechanical cues to immune reprogramming during Cancer progression. To target this pathway, we engineered mesoporous silica nanoparticles (mSNs) with tunable stiffness (253-1084.5 MPa), which were loaded with the Piezo1 agonist Yoda1 and TAMs-targeting peptide CRV (YmSNs@CRV) to precisely modulate TAMs mechanosignaling. Results demonstrated that softer 20% mSN achieved dual regulation of both macrophage phenotypic reprogramming and exosome-mediated communication via Piezo1 activation. Specifically, softer 20% mSNs enhanced pro-inflammatory markers (CD80), increased cytokine secretion, and promoted exosome production 5-fold more effectively than stiffer 80% mSNs. Proteomic analysis revealed that exosomes from 20% mSN-treated macrophages activated the TCR signaling, amplifying immune responses. In vivo, 20% YmSNs@CRV improved tumor penetration, repolarized TAMs toward an antitumor phenotype, and boosted cytotoxic T cell infiltration, significantly inhibiting tumor growth. This study integrates the mechanical characteristics of tumor tissues and proposes an "in situ mechanical dual-regulation" strategy, which combines mechano-regulated TAMs reprogramming with exosome-triggered immune responses, introducing a distinctive mechano-immunotherapeutic paradigm.

Keywords

Piezo1; TAMs; in situ mechanical regulation; tumor immunomodulation; tumor mechanobiology.

Figures
Products